IgD multiple myeloma: biology, diagnosis, and treatment

Egan, Philip; O’Connor, Sheila J.M.; Deighan, W. Ian; McConville, Conal; Elder, Patrick T; Morris, T. C. M.; Alexander, H. Denis

doi:10.1080/10428194.2022.2126280

Cited by 1 publication

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 The role of N-glycan biomarkers in the diagnosis and prognosis of IgD myeloma has also been studied. 31 Egan et al 32 reported on interphase fluorescence in situ hybridisation from 29 cases of IgD myeloma. They showed a decreased OS in patients aged ≥70 years, and better outcomes in those with κ light chain restriction.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Immunoglobin D Multiple Myeloma: A Single Centre Experience

Narayanan,

Menon,

M.T.

et al. 2024

EMJ

View full text Add to dashboard Cite

Background: Immunoglobulin D (IgD) myeloma is an uncommon subtype of multiple myeloma that accounts for 1-2% of all myeloma cases. IgD myeloma is often associated with a high incidence of renal insufficiency, hypercalcaemia, extraosseous disease, amyloidosis, and Bence-Jones proteinuria.Materials and Methods: The authors discuss the clinical presentation and treatment results of 12 cases of IgD myeloma, treated at a single centre.Results: The study included nine males and three females, with a median age of 48.5 years. All had lytic bone lesions, eight had anaemia, five had renal impairment, three had hypercalcaemia, three had features of amyloidosis, and one had polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome. On immunofixation electrophoresis, 10 patients had IgD λ subtype, and two had IgD κ. Urine Bence-Jones protein was positive for five patients. Eleven patients received bortezomib-based chemotherapy. Three patients achieved complete response, two had a very good partial response, two achieved partial response,three progressed, and one discontinued treatment. At 2 years, six patients were alive (50%). Median overall survival of the series was 21 months (range: 1-80 months).Conclusion: IgD myeloma is an uncommon subtype of myeloma associated with a high incidence of hypercalcaemia, renal insufficiency, extraosseous lesions, amyloidosis, and Bence-Jones proteinuria. IgD λ disease is more frequent, unlike other subtypes of IgD myeloma. Management is similar to other myeloma types, but with poorer outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Patients who were CD56-positive had longer survival than those lacking CD56. 32 Agbuduwe et al 33 compared the clinical characteristics and outcomes of patients with IgD myeloma from UK Phase III clinical trials, before 2002 and after 2002. IgD myeloma comprised 1.6% and 1.2% of the two groups, respectively.…”

Section: Resultsmentioning

confidence: 99%